US4808627A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of preventing or treating toxemia in pregnancy using a thromboxane A2 receptor antagonist
Assignee: ER Squibb and Sons LLC
•
Filing: 1987-12-16
•
Granted: 1989-02-28
•
Expires: 2007-12-16
Abstract
Abstract A method is provided for preventing or treating toxemia during pregnancy by administering a thromboxane A 2 receptor antagonist before or during toxemia.
Inventors
- 👤 Martin L. Ogletree
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 00:36
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/557; A61K31/185; A61K31/19; A61P; A61P13/00; A61P13/02; A61P15/00; A61P3/00; A61P43/00
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
35 words
A method for preventing or treating toxemia during pregnancy, in a mammalian species, which comprises administering to a mammalian species in need of such treatment an effective amount of a thromboxane A 2 receptor antagonist.
Claim 2
Independent Claim
35 words
A method for preventing or treating toxemia during pregnancy, in a mammalian species, which comprises administering to a mammalian species in need of such treatment an effective amount of a thromboxane A 2 receptor antagonist.
Claim 3
Dependent Claim
17 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is administered systemically.
Claim 4
Dependent Claim
19 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is administered intravenously or orally.
Claim 5
Dependent Claim
18 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is administered during toxemia.
Claim 6
Dependent Claim
23 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is administered during pregnancy prior to onset of toxemia.
Claim 7
Dependent Claim
20 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is a 7-oxabicycloheptane or a 7-oxabicycloheptene.
Claim 8
Dependent Claim
20 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is a 7-oxabicycloheptane substituted amino-prostaglandin analog.
Claim 9
Dependent Claim
21 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is a 7-oxabicycloheptane substituted diamide prostaglandin analog.
Claim 10
Dependent Claim
19 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is a phenoxyalkyl carboxylic acid.
Claim 11
Dependent Claim
19 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is a sulfonamidophenyl carboxylic acid.
Claim 12
Dependent Claim
19 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is an arylthioalkylphenyl carboxylic acid.
Claim 13
Dependent Claim
17 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist is [1S-[1α,2β(5Z),3β(1E,3R,4S),4α]]-7-[3-(3-hydroxy-4-phenyl-1-pentenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid.
Claim 14
Dependent Claim
23 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist has the name [1S-[1β,2α(5Z),3α,4β]]-7-[3-[[[[(1-oxoheptyl)amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or the corresponding tetrazole.
Claim 15
Dependent Claim
19 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist has the name [1S-[1α,2β(Z),3β,4α]]-7-[3-[[[[(4-cyclohexyl-1-oxobutyl)-amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid.
Claim 16
Dependent Claim
19 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist has the name [1S-[1α,2β(5Z),3β,4α]]-7-[3-[[2-(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2yl]-5-heptenoic acid.
Claim 17
Dependent Claim
20 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist has the name 4-(3-((4-chlorophenyl)sulfonyl)propyl)benzene acetic acid.
Claim 18
Dependent Claim
23 words
The method as defined in claim 1 wherein the thromboxane A 2 receptor antagonist has the name or 4-[2-(benzenesulfamido)ethyl]phenoxyacetic acid or 4-[2-(4-chlorobenzenesulfonamido)ethyl]phenylacetic acid.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-02-28 | 1992-08-29 | 1993-02-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-02-28 | 1996-08-29 | 1997-02-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-02-28 | 2000-08-29 | 2001-02-28 | $7700.00 | Window Closed / Lapsed |